High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
AbCellera Biologics (NASDAQ:ABCL) reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot flashes, associated with menopause. The randomized, double-blind, placebo-controlled study enrolled 92
Jazz Pharmaceuticals (NasdaqGS:JAZZ) expanded its collaboration with AbCellera Biologics to develop next-generation T-cell multispecific antibodies for gastrointestinal and other solid tumors. The company reported top-line results from the Phase 3 LAGOON trial of Zepzelca in second-line small cell lung cancer, which did not meet its primary endpoint. Zepzelca continues to have its first-line approval based on prior studies, and Jazz Pharmaceuticals is in discussions with the FDA about future...
ABSCI CORP (ABSI) delivered earnings and revenue surprises of +5.00% and -90.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.